REVELATION BIOSCIENCES INC
For the period ended Dec 31, 2023. Filed Mar 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 22, 2024
REVB$3.94-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year EndedDecember 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(120,254) | $(10,829,549) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 155,721 | 301,116 |
| Depreciation expense | 25,049 | 25,048 |
| Non-cash lease expense | — | 14,960 |
| Change in fair value of warrant liability | (8,328,937) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (11,559) | 569,044 |
| Deferred offering costs | 82,071 | (61,154) |
| Accounts payable | 749,660 | (666,042) |
| Accrued expenses | 161,963 | (592,987) |
| Operating lease liability | — | (16,752) |
| Accrued interest on Promissory Notes Payable & Convertible Note | — | 36,920 |
| Net cash used in operating activities | (7,286,286) | (11,219,396) |
| Cash flows from financing activities: | ||
| Proceeds from the Convertible Note | — | 2,500,000 |
| Repayment of the Convertible Note | — | (2,500,000) |
| Proceeds from the Business Combination, net | — | 11,923,499 |
| Proceeds from the PIPE Investment, net | — | 7,262,219 |
| Proceeds from Rollover Warrant exercise | — | 5,074 |
| Repurchase for the Forward Share Purchase Agreement exercise | — | (7,652,325) |
| Repayments of Promissory Notes Payable, including interest | — | (796,882) |
| Proceeds from the July 2022 Public Offering, net | — | 4,451,048 |
| Redemption of Series A Preferred Stock | (5,000) | 5,000 |
| Proceeds from the February 2023 Public Offering, net | 14,029,974 | — |
| Proceeds from Pre-Funded Warrants exercise | 34 | 13 |
| Net cash provided by financing activities | 14,025,008 | 15,197,646 |
| Net increase in cash and cash equivalents | 6,738,722 | 3,978,250 |
| Cash and cash equivalents at beginning of period | 5,252,979 | 1,274,729 |
| Cash and cash equivalents at end of period | $11,991,701 | $5,252,979 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Deferred offering costs included in accounts payable and accrued expenses | $66,033 | $26,017 |
| Fair Value of Class C Common Stock Warrants in connection with the February 2023 Public Offering | $13,996,500 | $— |
| Alternative cashless exercise of Class C Common Stock Warrants | $5,526,287 | $— |
| Current liabilities assumed in the Business Combination | $— | $2,149,432 |
| Deferred underwriting commissions assumed in the Business Combination | $— | $2,911,260 |
| Equity Issuance for fees in connection with the Business Combination | $— | $300 |
| Issuance of Class A Common Stock Warrants in connection with the PIPE Investment | $— | $3,634,262 |
| Issuance of Class A Placement Agent Common Stock Warrants in connection with the PIPE Investment | $— | $508,797 |
| Conversion of Accrued Expenses to Equity in connection with the Business Combination | $— | $749,700 |
| Issuance of Class B Common Stock Warrants in connection with the July 2022 Public Offering | $— | $4,490,457 |
| Issuance of Class B Placement Agent Common Stock Warrants in connection with the July 2022 Public Offering | $— | $310,137 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.